Jump to any asset
849 assets, updated daily
As of September 15, 2026, Eli Lilly and Company (LLY) trades at $1,146.56. CleaRank Financial AI rates it Buy with a fair value of $1,385.00, 20.8% above the current price. Wall Street's consensus target is $1,385.00 across 30 analysts. RSI at 22 is in oversold territory, and the price is below its 50-day average of $1,182.07.
Eli Lilly and Company (LLY)
Eli Lilly and Company NYSE
$1,146.56
8.280 (0.73%)
Latest Price
AI Analyst Consensus
73 / 100
Eli Lilly and Company (LLY) is currently trading at $1146.56, below its 50-day Simple Moving Average (SMA) of $1182.07, indicating a short-term bearish technical signal. However, the stock remains above its 200-day SMA of $1065.37, suggesting a longer-term bullish trend is intact. The Relative Strength Index (RSI) is at 22.1, signaling oversold conditions and a potential for a rebound. Analyst sentiment is overwhelmingly positive, with a consensus rating of Buy and a median price target of $1385.00, implying an upside of 20.8%. The company is experiencing exceptional revenue growth, projected at 35.00% for the current year and 15.00% for the next, far exceeding sector averages. Eli Lilly's strong profit margins and return on equity further support its fundamental strength, making it an attractive investment despite its current technical pullback.
LLY Price Analysis
Market Metrics
Open
$1,154.82
Day Range
$1,140.93 to $1,160.60
Prev Close
$1,138.28
Volume
27.9K
52-Week Range
$712.05 to $1,292.65
Market Cap
$1.01T
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Valuation is broadly in line with sector peers (20% difference), suggesting fair market pricing relative to industry standards.
LLY Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, LLY beat estimates 4 times. The stock rose 3 times the next day. Price tends to react positively to beats.
LLY Analysis
Company's Health
5/5
12-Month Analyst Target
+20.80% Upside
Median of 30 analysts (12-month)
$1,385.00
AI Technical Analysis
Eli Lilly and Company (LLY) is currently trading below its 50-day SMA of $1182.07, indicating a bearish short-term trend, but remains above its 200-day SMA of $1065.37, suggesting the longer-term uptrend is still in place. The stock's RSI is at 22.1, firmly in oversold territory, which historically suggests a potential for a price reversal upwards. The MACD indicator is at -16.95, also pointing to bearish momentum. Key support is identified at the 200-day SMA ($1065.37), while resistance lies near the 50-day SMA ($1182.07) and the current price is approaching the lower bound of its recent trading range. Volume has been significantly below average recently, suggesting a lack of strong conviction from traders during this pullback. The chart structure indicates that while short-term momentum is negative, the underlying long-term trend remains positive, with the oversold RSI presenting a potential buying opportunity for investors anticipating a bounce.
ProTips
- Eli Lilly and Company (LLY) has an oversold RSI of 22.1, suggesting a potential short-term buying opportunity as the stock may be due for a bounce.
- Despite significant insider selling, the narrative indicates it stems from parent company divestitures, not management's lack of conviction, making it a neutral signal.
- Consider the premium valuation of LLY; while justified by growth, any slowdown in its pipeline could lead to a significant price correction.
Key Catalysts
Bullish
Strong Earnings Beat in Q2 2026
Eli Lilly and Company (LLY) reported EPS of $8.38, exceeding estimates by 27.36%, driving a 1.89% stock price increase and reinforcing positive investor sentiment.
Source: Company Earnings ReportBullish
Projected Revenue Growth Exceeds Sector Average
With current year revenue growth projected at 35.00% and next year at 15.00%, LLY significantly outpaces the Healthcare sector's median revenue growth of 8.1%.
Source: Analyst EstimatesNeutral
Parent Company Divestiture
LILLY ENDOWMENT, INC. has been systematically reducing its stake in LLY, representing $3.9 billion in sales, as part of a corporate restructuring rather than a bearish signal from management.
Source: Insider Transaction DataBullish
Oversold Technical Conditions
The current RSI of 22.1 indicates that LLY is in oversold territory, suggesting a potential for a short-term price rebound.
Source: Technical AnalysisMarket Outlook
Eli Lilly and Company (LLY) is expected to continue its strong growth trajectory over the next 6-12 months, driven by its innovative drug pipeline and expanding market share. The company's projected revenue growth of 35.00% for the current year and 15.00% for the next year, significantly outpacing sector averages, underpins a positive base case scenario. Analysts have a median price target of $1385.00, suggesting potential upside from the current price. Key upside catalysts include successful clinical trial results and new drug approvals, which could further accelerate revenue and earnings growth. Conversely, potential risks include increased competition from other pharmaceutical companies, regulatory hurdles, or any unexpected clinical trial failures. The current oversold technical condition, with an RSI of 22.1, presents a favorable entry point for investors anticipating a rebound.
Key Statistics
| Market Cap | 1.01T |
|---|---|
| P/E Ratio | 38.17 |
| EPS (TTM) | 29.82 |
| Dividend Yield | 0.58% |
| 52 Week High | 1,292.65 |
| 52 Week Low | 712.05 |
Eli Lilly and Company (LLY) exhibits a P/E ratio of 38.17, which is higher than the sector median of 31.9, suggesting a premium valuation. However, its Price-to-Sales (P/S) ratio of 12.74 is also above the sector median of 3.7, but this is supported by exceptional revenue growth of 47.7% year-over-year and projected growth of 35.00% for the current year. The company demonstrates outstanding profitability with a net profit margin of 33.53% and a return on equity (ROE) of 102.29%, significantly outperforming the sector's ROE of 6.9%. Its debt-to-equity ratio of 1.62 is slightly above the sector average, but given its strong profitability and growth, it appears manageable. The current valuation, while high, is justified by its leading position in drug manufacturing and its impressive growth trajectory.
Earnings & Growth Analysis
Eli Lilly and Company (LLY) has consistently beaten earnings expectations, most recently reporting an EPS of $8.38 for the quarter ending June 2026, which was 27.36% above the estimated $6.58, leading to a 1.89% price increase. This follows a pattern of strong performance, with the company also exceeding estimates in the prior two quarters. The company's revenue growth is strong, with current quarter estimates showing a 26.00% year-over-year increase, indicating sustained demand for its products.
Key Risks
Eli Lilly and Company (LLY) faces valuation risk, with its P/E ratio of 38.17 significantly higher than the sector median of 31.9, indicating that the stock may be overvalued relative to its peers. Despite strong insider selling, the narrative indicates this is primarily driven by parent company divestitures, not management's lack of confidence. However, any unexpected slowdown in its drug pipeline or increased competition could pressure its premium valuation.
Technical Indicators
| RSI (14) | 22.10 |
|---|---|
| MACD | -16.95 |
| SMA 50 | 1,182.07 |
| SMA 200 | 1,065.37 |
RSI
Oversold
SMA Cross
Bullish
Price vs SMA
Bearish
MACD
Bearish
Golden Cross in effect with the 50-day SMA ($1,182.07) above the 200-day SMA ($1,065.37), price is trading below the 50-day SMA, RSI at 22.1 suggests oversold conditions; potential bounce setup.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.27
Weak correlation
Nasdaq 100 (QQQ)
+0.18
Weak correlation
Bitcoin (BTC)
-0.15
Weak correlation
Gold (XAU)
+0.13
Weak correlation
Check Custom Correlation
How does any other asset move with LLY? One year of daily closes, Pearson correlation.
Try
LLY Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$1,123.63
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$1,146.56
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$1,085.76
MAX LOSS
-3.4%
Volatility-Adjusted Stop Loss
Calculated based on RSI (22.1) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$1,179.81
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$1,235.99
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$1,292.17
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for LLY is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 15, 2026.Growth of $10,000
A $10,000 investment in LLY in September 2016 would be worth about $144,415 today, compared with about $35,344 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in LLY today could grow to about $43,642 by 2036 in the base case, with a bull case near $149,490 and a bear case around $12,741. Projections are statistical simulations, not guarantees.
LLY Stock Price Prediction: 2030
CleaRank's simulation projects a price near $2,067 for LLY by 2030 in the base case, from $1,147 today (1.8x over 4 years). The downside path ends near $949. These are outcomes of a Monte Carlo simulation run on LLY's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $900 | $1,329 | $1,961 |
| 2028 | $888 | $1,539 | $2,670 |
| 2029 | $909 | $1,784 | $3,501 |
| 2030 | $949 | $2,067 | $4,503 |
| 2031 | $1,003 | $2,395 | $5,721 |
| 2032 | $1,069 | $2,775 | $7,203 |
| 2033 | $1,148 | $3,216 | $9,009 |
| 2034 | $1,239 | $3,727 | $11,209 |
| 2035 | $1,343 | $4,318 | $13,886 |
| 2036 | $1,461 | $5,004 | $17,140 |
Method: 10,000 simulated price paths using LLY's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
LLY Insider Trading Analysis
Bought
$4.5M
8 Transactions
Sold
$3.9B
46 Transactions
Insiders
25
Active Traders
Avg Transaction
$71.9M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jan 7, 2026 | LILLY ENDOWMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 292.1K | $322.4M |
| Nov 12, 2025 | LILLY ENDOWMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 305.0K | $308.4M |
| Nov 11, 2025 | LILLY ENDOWMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 283.1K | $279.3M |
| Nov 3, 2025 | LILLY ENDOWMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 300.0K | $266.6M |
| Oct 31, 2025 | LILLY ENDOWMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 301.3K | $260.2M |
| Jul 24, 2025 | LILLY ENDOWMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 280.0K | $225.4M |
| Mar 3, 2025 | LILLY ENDOWMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 220.0K | $204.3M |
| Feb 25, 2025 | LILLY ENDOWMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 225.0K | $203.2M |
| Jul 10, 2024 | LILLY ENDOWMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 210.0K | $197.4M |
| Feb 6, 2025 | LILLY ENDOWMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 210.0K | $183.6M |
Page 1 of 1
Frequently Asked Questions
What is Eli Lilly and Company's stock price forecast for 2030?
Eli Lilly and Company's (LLY) stock price is projected to reach a base case of $2067.08 by 2030, according to Monte Carlo simulations. The downside scenario suggests a price of $948.80, while the upside scenario projects $4503.37. These are statistical outcomes, not guarantees.
Is Eli Lilly and Company stock a buy right now?
Eli Lilly and Company (LLY) is rated a Buy by Wall Street analysts, with a median price target of $1385.00, suggesting a 20.8% upside from the current price of $1146.56. The stock's RSI is oversold at 22.1, indicating a potential buying opportunity.
What is Eli Lilly and Company's current valuation compared to its sector?
Eli Lilly and Company (LLY) trades at a P/E ratio of 38.17 and a P/S ratio of 12.74, both higher than the Healthcare sector medians of 31.9 and 3.7, respectively. This premium valuation is supported by its exceptional revenue growth and profitability.
How has Eli Lilly and Company performed in recent earnings reports?
Eli Lilly and Company (LLY) has consistently beaten earnings estimates, most recently reporting an EPS of $8.38 for the quarter ending June 2026, a 27.36% surprise. This strong performance has contributed to positive price reactions in recent quarters.
What are the main risks facing Eli Lilly and Company?
The primary risks for Eli Lilly and Company (LLY) include its high valuation multiples (P/E of 38.17) and potential competitive pressures in the drug manufacturing sector. Any setbacks in its drug development pipeline could also impact its growth trajectory.
What is the insider sentiment for Eli Lilly and Company?
Insider sentiment for Eli Lilly and Company (LLY) is characterized as a parent company divestiture, with $3.9 billion in sales primarily from LILLY ENDOWMENT, INC. This indicates corporate restructuring rather than a lack of confidence from management, with officer and director selling totaling a more modest $23 million.
What is the long-term growth outlook for Eli Lilly and Company?
Eli Lilly and Company (LLY) has a strong long-term growth outlook, with projected revenue growth of 15.00% for next year and an average annual growth rate of 31.51% projected over the next five years. This is driven by its strong drug pipeline and market leadership.